Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
1997-4-22
|
| pubmed:abstractText |
A total of 71 men with clinical T1b-T2c carcinoma of the prostate underwent ultrasound-guided interactive seed implantation of the prostate. Sixty received 125I and II 103Pd implants. A laparoscopic lymph node dissection was performed in 58 patients. The patients have been followed a mean of 2 years (1-4.2 years). With use of a prostate specific antigen (PSA) value of 1 ng/ml, patients (n = 8) who presented with an initial PSA of < or = 4.0 ng/ml were all free from failure. This compared with those who presented with an initial PSA of 4.1-10, 10.1-20, and > or = 20 ng/ml, in whom the freedom from failure rates were 52, 32, and 22%, respectively. Patients (n = 49) who presented with an initial PSA of less than or equal to 15 ng/ml had a median PSA of 0.88 ng/ml at last follow-up compared with 2.25 ng/ml for those with an initial PSA of > 15 ng/ml. Prostate biopsies performed 18-24 months after implantation were negative in 82%. The median PSA for those with a negative biopsy was 0.7 ng/ml vs. 4.9 ng/ml for those with a positive biopsy. There were no long-term persistent urinary complaints. Grade 2 radiation proctitis occurred in three (4.2%). No cases of severe radiation proctitis or cystitis occurred. Urinary retention occurred in four patients (5.6%), one of whom required a transurethral resection of the prostate. No patients developed urinary incontinence. Potency was preserved in 94%. We conclude that the real-time ultrasound-guided transperineal seed implantation technique is an effective and safe method of treating prostate cancer. Longer follow-up is needed to substantiate these early encouraging results.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Indium Radioisotopes,
http://linkedlifedata.com/resource/pubmed/chemical/Palladium,
http://linkedlifedata.com/resource/pubmed/chemical/Prostate-Specific Antigen,
http://linkedlifedata.com/resource/pubmed/chemical/Radioisotopes,
http://linkedlifedata.com/resource/pubmed/chemical/Radiopharmaceuticals
|
| pubmed:status |
MEDLINE
|
| pubmed:issn |
1079-3259
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
1
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
72-80
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:9118374-Biopsy,
pubmed-meshheading:9118374-Brachytherapy,
pubmed-meshheading:9118374-Carcinoma,
pubmed-meshheading:9118374-Cystitis,
pubmed-meshheading:9118374-Disease-Free Survival,
pubmed-meshheading:9118374-Follow-Up Studies,
pubmed-meshheading:9118374-Humans,
pubmed-meshheading:9118374-Indium Radioisotopes,
pubmed-meshheading:9118374-Laparoscopy,
pubmed-meshheading:9118374-Lymph Node Excision,
pubmed-meshheading:9118374-Male,
pubmed-meshheading:9118374-Neoplasm Staging,
pubmed-meshheading:9118374-Palladium,
pubmed-meshheading:9118374-Penile Erection,
pubmed-meshheading:9118374-Proctitis,
pubmed-meshheading:9118374-Prostate-Specific Antigen,
pubmed-meshheading:9118374-Prostatectomy,
pubmed-meshheading:9118374-Prostatic Neoplasms,
pubmed-meshheading:9118374-Radiation Injuries,
pubmed-meshheading:9118374-Radioisotopes,
pubmed-meshheading:9118374-Radiopharmaceuticals,
pubmed-meshheading:9118374-Safety,
pubmed-meshheading:9118374-Ultrasonography, Interventional,
pubmed-meshheading:9118374-Urinary Incontinence,
pubmed-meshheading:9118374-Urinary Retention
|
| pubmed:year |
1995
|
| pubmed:articleTitle |
Brachytherapy for prostate cancer: real-time three-dimensional interactive seed implantation.
|
| pubmed:affiliation |
Department of Urology, Mount Sinai School of Medicine, New York, New York, USA.
|
| pubmed:publicationType |
Journal Article,
Comparative Study
|